Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) patients experience lower health-related quality of life (HRQoL) than the general population. In clinical trials, natalizumab significantly improved HRQoL and reduced relapse rates and disability progression in patients with relapsing MS. In a 1-year analysis of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Foley, John F, Nair, Kavita V, Vollmer, Timothy, Stephenson, Judith J, Niecko, Timothy, Agarwal, Sonalee S, Watson, Crystal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481282/
https://www.ncbi.nlm.nih.gov/pubmed/28670113
http://dx.doi.org/10.2147/PPA.S134865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481282/
https://www.ncbi.nlm.nih.gov/pubmed/28670113
http://dx.doi.org/10.2147/PPA.S134865

Ejemplares similares